OP-3136
Breast Cancer and Other Solid Tumors (e.g., CRPC, Lung Cancer)
Key Facts
About Olema Oncology
Olema Oncology is a clinical-stage biotech focused on transforming the treatment of endocrine-driven cancers, particularly metastatic ER+/HER2- breast cancer. Its core achievement is the development of palazestrant, an oral CERAN/SERD with a dual mechanism of action, now in two pivotal Phase 3 trials with top-line monotherapy data expected in fall 2026. The company's strategy leverages deep scientific expertise in nuclear receptors to address the critical unmet need of therapy resistance, aiming to establish palazestrant as a new standard of care. A second asset, OP-3136, a KAT6 inhibitor, represents a novel epigenetic approach currently in Phase 1.
View full company profileAbout Olema Pharmaceuticals
Olema Pharmaceuticals is a clinical-stage biotech company focused on transforming the treatment paradigm for metastatic breast cancer, particularly ER+/HER2- disease. Its core achievement is advancing palazestrant, a potentially best-in-class oral CERAN, into two pivotal Phase 3 trials (OPERA-01 and OPERA-02) with top-line monotherapy data expected in fall 2026. The company's strategy is built on a proprietary platform for complete estrogen receptor antagonism and extends to targeting epigenetic drivers like KAT6 with its earlier-stage candidate, OP-3136. Olema aims to provide more effective, convenient, and durable therapies for patients who have progressed on prior endocrine treatments.
View full company profile